Publication Month: Apr 2021 | Report Code: TIPRE00003406 | No. of Pages: 161 | Category: Pharmaceuticals | Status: Published
Antibiotics are powerful medicines that are used to fight against bacterial infections and diseases. These are specifically used to treat infections caused by bacteria such as, Staph., Strep., or E. coli. Antibiotics either kill the bacteria (bactericidal) or restrict it from reproducing and growing (bacteriostatic). The antibiotics market do not work against any viral infection. Some of the common infections treated with antibiotics are, conjunctivitis, skin or soft tissue infection, upper respiratory tract infection, bronchitis, streptococcal pharyngitis (strep throat), and among others.
A generic medicine is a copy of a branded drug that is no longer under patent. Generic versions are introduced in the market with an aim to offer cost-efficient drugs and increase the reach of these drugs to people belonging to different economic classes. Generic versions are popular due to their availability and affordability. For instance, according to a study published on the NCBI in 2018, the average brand name prescription price was almost 4-times the average generic price. Additionally, the companies are also focusing on the development of generic versions with an aim to offer antibiotics at minimal costs. For instance, in June 2018, Lupin launched generic Tobramycin inhalation solution in the US market. Further, encouragement from government authorities is also projected to drive the production of generic antibiotics, which would eventually drive the growth of the antibiotics market during the forecast period. For instance, in February 2019, the US Food and Drug Administration (US FDA) announced approval for commercialization of generic medicines manufactured by Indian drug companies in the US.
Based on drug class, the antibiotics market is segmented into sulfonamides, aminoglycosides, carbapenem, macrolides, fluoroquinolones, penicillin, cephalosporin, and others. The cephalosporin segment held the largest share of the market in 2020; whereas the fluoroquinolones segment is anticipated to register the highest CAGR in the market during the forecast period.
Based on action mechanism, the antibiotics market has been segmented into mycolic acid inhibitors, RNA synthesis inhibitors, DNA synthesis inhibitors, protein synthesis inhibitors, and cell wall synthesis inhibitors. The cell wall synthesis inhibitors segment held the largest share of the market in 2020, whereas the DNA synthesis inhibitors segment is estimated to register the highest CAGR in the market during the forecast period.
|Market Size Value in||US$ 44,111.31 Million in 2020|
|Market Size Value by||US$ 59,253.24 Million by 2028|
|Growth rate||CAGR of 4.0% from 2021-2028|
|No. of Pages||161|
|No. of Tables||49|
|No. of Charts & Figures||70|
|Historical data available||Yes|
|Segments covered||Drug Class ; Action Mechanism , and Geography|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
Product launches and approval strategies are commonly adopted by companies to expand their footprint and product portfolio worldwide and meet the growing demand.
The market players operating in the antibiotics market adopt the strategy of expansion to enlarge customer base across the world, which also permits the players to maintain their brand name globally. For instance, in July 2019, the company such as Pfizer has launched an international research consortium to discover and develop new TB antibiotics in collaboration with eight biotechnology partners and European academic.
The List of Companies - Antibiotics Market